These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27436471)

  • 1. Intracellular activity of a membrane-active glycopeptide antibiotic against meticillin-resistant Staphylococcus aureus infection.
    Yarlagadda V; Samaddar S; Haldar J
    J Glob Antimicrob Resist; 2016 Jun; 5():71-4. PubMed ID: 27436471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455.
    Yarlagadda V; Konai MM; Manjunath GB; Prakash RG; Mani B; Paramanandham K; Ranjan SB; Ravikumar R; Chakraborty SP; Roy S; Haldar J
    Int J Antimicrob Agents; 2015 Jun; 45(6):627-34. PubMed ID: 25900818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus.
    Gould IM
    Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
    Arhin FF; Sarmiento I; Moeck G
    Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
    Belley A; Lalonde Seguin D; Arhin F; Moeck G
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4342-5. PubMed ID: 27067327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006-2011 in China.
    Zhuo C; Xu YC; Xiao SN; Zhang GY; Zhong NS
    Int J Antimicrob Agents; 2013 Jun; 41(6):578-81. PubMed ID: 23562222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P; Huggler E; Arhin FF; Moeck G; Renzoni A; Lew DP
    Int J Antimicrob Agents; 2009 Dec; 34(6):540-3. PubMed ID: 19744838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA).
    Pumerantz A; Muppidi K; Agnihotri S; Guerra C; Venketaraman V; Wang J; Betageri G
    Int J Antimicrob Agents; 2011 Feb; 37(2):140-4. PubMed ID: 21130608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of linezolid against Panton-Valentine leukocidin (PVL)-positive meticillin-resistant Staphylococcus aureus (MRSA) in a mouse model of haematogenous pulmonary infection.
    Yanagihara K; Kihara R; Araki N; Morinaga Y; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Tsukamoto K; Kamihira S
    Int J Antimicrob Agents; 2009 Nov; 34(5):477-81. PubMed ID: 19665359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.
    del Río A; García-de-la-Mària C; Entenza JM; Gasch O; Armero Y; Soy D; Mestres CA; Pericás JM; Falces C; Ninot S; Almela M; Cervera C; Gatell JM; Moreno A; Moreillon P; Marco F; Miró JM;
    Antimicrob Agents Chemother; 2016 Jan; 60(1):478-86. PubMed ID: 26525803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus.
    Huang V; Cheung CM; Kaatz GW; Rybak MJ
    Int J Antimicrob Agents; 2010 Jan; 35(1):25-9. PubMed ID: 19900792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
    Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
    Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
    Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
    Huang V; Brown WJ; Rybak MJ
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.